These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

872 related items for PubMed ID: 25388687

  • 1. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.
    Sampson KE, Brinker A, Pratt J, Venkatraman N, Xiao Y, Blasberg J, Steiner T, Bourner M, Thompson DC.
    Drug Metab Dispos; 2015 Feb; 43(2):199-207. PubMed ID: 25388687
    [Abstract] [Full Text] [Related]

  • 2. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
    Graber-Maier A, Gutmann H, Drewe J.
    Mol Pharm; 2010 Oct 04; 7(5):1618-28. PubMed ID: 20701289
    [Abstract] [Full Text] [Related]

  • 3. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
    Mease K, Sane R, Podila L, Taub ME.
    J Pharm Sci; 2012 May 04; 101(5):1888-97. PubMed ID: 22359351
    [Abstract] [Full Text] [Related]

  • 4. Regulation of expression and activity of multidrug resistance proteins MRP2 and MDR1 by estrogenic compounds in Caco-2 cells. Role in prevention of xenobiotic-induced cytotoxicity.
    Arias A, Rigalli JP, Villanueva SS, Ruiz ML, Luquita MG, Perdomo VG, Vore M, Catania VA, Mottino AD.
    Toxicology; 2014 Jun 05; 320():46-55. PubMed ID: 24685904
    [Abstract] [Full Text] [Related]

  • 5. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
    Dahan A, Amidon GL.
    Am J Physiol Gastrointest Liver Physiol; 2009 Aug 05; 297(2):G371-7. PubMed ID: 19541926
    [Abstract] [Full Text] [Related]

  • 6. The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells.
    Ye L, Yang X, Yang Z, Gao S, Yin T, Liu W, Wang F, Hu M, Liu Z.
    Toxicol Lett; 2013 Feb 04; 216(2-3):86-99. PubMed ID: 23200901
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines.
    Mukkavilli R, Jadhav G, Vangala S.
    Curr Pharm Biotechnol; 2017 Feb 04; 18(14):1151-1158. PubMed ID: 29521222
    [Abstract] [Full Text] [Related]

  • 8. Knockout Transporter Cell Lines to Assess Substrate Potential Towards Efflux Transporters.
    Volpe DA.
    AAPS J; 2024 Jul 10; 26(4):79. PubMed ID: 38981917
    [Abstract] [Full Text] [Related]

  • 9. High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.
    Karlsson JE, Heddle C, Rozkov A, Rotticci-Mulder J, Tuvesson O, Hilgendorf C, Andersson TB.
    Drug Metab Dispos; 2010 Apr 10; 38(4):705-14. PubMed ID: 20071452
    [Abstract] [Full Text] [Related]

  • 10. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.
    Ma L, Qin Y, Shen Z, Bi H, Hu H, Huang M, Zhou H, Yu L, Jiang H, Zeng S.
    J Ethnopharmacol; 2015 Aug 22; 172():430-5. PubMed ID: 26183576
    [Abstract] [Full Text] [Related]

  • 11. Characterization of efflux transporters involved in distribution and disposition of apixaban.
    Zhang D, He K, Herbst JJ, Kolb J, Shou W, Wang L, Balimane PV, Han YH, Gan J, Frost CE, Humphreys WG.
    Drug Metab Dispos; 2013 Apr 22; 41(4):827-35. PubMed ID: 23382458
    [Abstract] [Full Text] [Related]

  • 12. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.
    Cholkar K, Trinh HM, Vadlapudi AD, Wang Z, Pal D, Mitra AK.
    J Ocul Pharmacol Ther; 2015 May 22; 31(4):248-55. PubMed ID: 25844889
    [Abstract] [Full Text] [Related]

  • 13. Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice.
    Tian X, Li J, Zamek-Gliszczynski MJ, Bridges AS, Zhang P, Patel NJ, Raub TJ, Pollack GM, Brouwer KL.
    Antimicrob Agents Chemother; 2007 Sep 22; 51(9):3230-4. PubMed ID: 17576841
    [Abstract] [Full Text] [Related]

  • 14. Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP.
    Kowalski P, Surowiak P, Lage H.
    Mol Ther; 2005 Apr 22; 11(4):508-22. PubMed ID: 15771954
    [Abstract] [Full Text] [Related]

  • 15. Silencing the breast cancer resistance protein expression and function in caco-2 cells using lentiviral vector-based short hairpin RNA.
    Zhang W, Li J, Allen SM, Weiskircher EA, Huang Y, George RA, Fong RG, Owen A, Hidalgo IJ.
    Drug Metab Dispos; 2009 Apr 22; 37(4):737-44. PubMed ID: 19131524
    [Abstract] [Full Text] [Related]

  • 16. Genomic Knockout of Endogenous Canine P-Glycoprotein in Wild-Type, Human P-Glycoprotein and Human BCRP Transfected MDCKII Cell Lines by Zinc Finger Nucleases.
    Gartzke D, Delzer J, Laplanche L, Uchida Y, Hoshi Y, Tachikawa M, Terasaki T, Sydor J, Fricker G.
    Pharm Res; 2015 Jun 22; 32(6):2060-71. PubMed ID: 25522789
    [Abstract] [Full Text] [Related]

  • 17. Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters.
    Te Brake LH, Russel FG, van den Heuvel JJ, de Knegt GJ, de Steenwinkel JE, Burger DM, Aarnoutse RE, Koenderink JB.
    Tuberculosis (Edinb); 2016 Jan 22; 96():150-7. PubMed ID: 26682943
    [Abstract] [Full Text] [Related]

  • 18. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
    Andersen V, Svenningsen K, Knudsen LA, Hansen AK, Holmskov U, Stensballe A, Vogel U.
    World J Gastroenterol; 2015 Nov 07; 21(41):11862-76. PubMed ID: 26557010
    [Abstract] [Full Text] [Related]

  • 19. Application and limitation of inhibitors in drug-transporter interactions studies.
    Wang Q, Strab R, Kardos P, Ferguson C, Li J, Owen A, Hidalgo IJ.
    Int J Pharm; 2008 May 22; 356(1-2):12-8. PubMed ID: 18272304
    [Abstract] [Full Text] [Related]

  • 20. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
    Ye D, Harder A, Fang Z, Weinheimer M, Laplanche L, Mezler M.
    Pharm Res; 2020 Sep 11; 37(10):194. PubMed ID: 32918191
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.